The Value of Support Groups

Dorothy Leone-Glasser, RN, HHC, CEO Advocates for Responsible Care,

Chair Georgia Bio Patient Advocacy Alliance

When I was diagnosed with systemic lupus erythematosus at 19 years, I discovered a major void in the treatment of chronic illness –support counseling to help patients understand and cope with the challenges of their disease. To bridge this gap in my own practice as a Nurse Specialist, I took a 3-year internship in Chronic Illness Counseling at Columbia University, NYC.  I was determined to fill that void so I created, a national award winning, Coping with Chronic Illness Project. The major component was providing support groups for those with chronic and terminal illness and their caregivers. The groups offered information and practical life-style engineering methods to address the physical and psychological aspects of illness, coping methods, pain and stress management strategies and communication and relationship skills with navigation approaches to our complex healthcare system.

Today we are partnering with GA Bio-Center for Global Health Innovation (CGHI) to focus on the science of patient input for medical research and development with consideration of downstream regulatory and legislative policy decision making.  In doing so, we can explore gaps in knowledge and other barriers that impede progress, and discuss the value of patient input for research that addresses gaps and barriers that could help move the patient and Bio community forward.

To understand the value of support groups on our patient community, Rx in Reach and CGHI launched a digital campaign to collect survey responses from Georgians about chronic illness support groups through Facebook Ads.

The survey generated 157 responses with 49% of all responders saying they belonged to a chronic illness support group. Although, 45% of all responders said they don’t belong to a support group for chronic illness; 63% of all responders said they would like to join a support group.

Other interesting findings from our survey were:

  • 60% believe support groups are misunderstood 
  • 46% said there a stigma associated with support groups that could lead to members feeling embarrassed
  • Responders stated they joined a support group because of
    • feeling isolated
    • needing help managing illness
    • needing someone to listen
    • their physician suggested it

Our findings show there is a strong stigma associated with seeking help from a support group. Support group members believe the public does not understand the need to connect with others who understand their daily challenges of living with chronic illness. Professional facilitated support groups offer a safe, non-judging environment for people to gain valuable information about disease processes, managing illness symptoms and healthcare system barriers while providing worthwhile life-style engineering to better cope with the rollercoaster of emotions and daily living complications. Survey responders, 20%, stated, their support group experience helped them, especially to feel less isolated and 15% of responders stated their group offered them the opportunity to gain new friends who understand their illness journey.

Summary

We know there are many with chronic illness, their caregivers, family members and friends who would want the chance to join a support group. This presents an opportunity for us to extend our outreach to those who are facing illness feeling alone and misunderstood so we can ensure their voices are heard with aid and encouragement offered to help them live their best life despite being ill. The work of this Patient Advocacy Alliance will continue to bring together our Bio community, patient support group members, advocate and medical organizations to improve health equity throughout our healthcare delivery system and clinical trials, while sharing strategy and actions that address important health policy issues.

Panelists

Kelly Barta headshot

Kelly Barta

Coalition of Skin Diseases, President

After experiencing a prolonged and severe health crisis due to long-term use of topical steroids for eczema, Kelly became a passionate voice for those who were suffering. She was determined to bring change to the way eczema was understood and treated. Her advocacy efforts have led her to serve on several national dermatology nonprofits, bringing awareness to the great needs of this community and supporting those living with eczema and going through topical steroid withdrawal syndrome.

Kelly currently serves as President and CEO of the Coalition of Skin Diseases, an umbrella organization of more than 25 national skin-related patient groups, which exists to raise awareness of skin diseases and advocate for the 84+ million Americans living with skin conditions.

She has served as past president of the International Topical Steroid Awareness Network (ITSAN), and continues to support their mission as member of the Board of Directors. Additionally, Kelly sits on the Patient Advocacy Task Force of the American Academy of Dermatology and the Atopic Dermatitis Advisory Panel for Globalskin. She has presented on eczema and TSW to the FDA as well as before patient, academic and political audiences. Kelly is the recent author of her story, To Eczema With Love, https://toeczemawithlove.com/.

Kelly resides in Atlanta, Georgia with her two sons and enjoys taking in the great outdoors, whether it be the mountains, oceans, a walk in the woods or digging in her own garden.

Barbara Fleeman headshot

Barbara Fleeman

WomenHeart Champion; Support Group Facilitator

Barbara grew up in Atlanta and moved back 6 years ago after spending 40 years building a successful career in entertainment consumer marketing/promotion.  She was always very active in her personal and professional life.  In 2013 she was diagnosed with severe pericarditis.  Over the following 18 months. She continued to experience increasingly difficult episodes of shortness of breath, chest pain, fatigue, nausea, dizziness, and chest pressure.  She went to see several doctors and was told that there was nothing wrong with her heart, even though she told them “My heart hurts”.  She continued to become sicker.  After a long course of indecision by medical professionals, she found help and a correct diagnosis of INOCA and Coronary Microvascular Dysfunction at the Barbra Streisand Women’s Heart Center at Cedars Sinai Medical Center in Los Angeles.

In 2015 she was invited to attend the WomenHeart Science and Leadership Symposium at the Mayo Clinic in Rochester, MN.  After an intensive five-day event, she was trained to become a WomenHeart Champion.  Barbara continues to share her experience with women to help educate them to the unique signs & symptoms of women’s heart disease, as well as, provide patient advocate support to women who are living with or at risk of heart disease.

Christopher Reed headshot

J. Christopher Reed

Lupus Foundation of America-Georgia

Support Group Facilitator, Advocacy Chair

Christopher was diagnosed with lupus in 1990 at the age of 16. Lupus attacked his heart, lungs, kidneys, digestive system, veins, and nervous system. Christopher’s lupus journey began with chronic headaches and frequent muscle spasms then progressed to frequent fevers, arthritis, and tremendous weight loss. He was barely able wrap his hands around the steering wheels during driver’s ed class and walking up the stairwell to his bedroom felt like he was having a heart attack. In 2004, he developed stage 3 kidney disease.  With his first job out of law school, Christopher was juggling kidney disease and horrible chemotherapy treatments. In 2018, he almost lost his life due to septic shock.

Overtime, Christopher continued to suffer from severe organ involvement. He was constantly worried about a lack of insurance and the cost of his life-saving medication.

Despite these serious lupus attacks, and moving back to his parent’s home, Christopher earned a bachelor’s degree with honors from the Georgia State University and a law degree from Tulane University. He attributes his success to God, the support of family and the support received at an early age from the Lupus Foundation of America, Georgia Chapter (LFAGA).

In speaking with Christopher, one can tell he is an avid advocate passionate about tackling healthcare policy and increasing lupus research. He previously chaired the Georgia Council on Lupus Education and Awareness (Council), a sponsored entity created by the state legislature to improve the lives of Georgians living with lupus.  He has worked to establish the Georgia Lupus Collaborative, an advisory group and think tank charged with improving the lives of people with lupus in Georgia.

Christopher currently serves as a Support Group Facilitator, Advocacy Chair, and Project Manager for the Lupus Foundation of America-Georgia Chapter. His support group is specifically designed for men. As Advocacy Chair, he gives presentations on patient advocacy and public health policy as well as being a writer on Lupus. Each year, over a one hundred lupus advocates engage in Lupus Day at the Georgia State Capitol. He remains involved in Health Research and serves to increase African American participation in clinical trials through a series of education sessions, open discussion, and dialogues with African American physicians and African American researchers.

Christopher has been honored to be a recipient of several awards including the Mary Cann Achievement Award from the Lupus Foundation of America, Georgia Chapter.

The post The Value of Support Groups appeared first on Georgia Bio.

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology
April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities
April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS